DOXYLAMINE SUCCINATE AND PYRIDOXINE HYDROCHLORIDE

Post-LOE

doxylamine succinate and pyridoxine hydrochloride

Teva

ANDAORALTABLET, DELAYED RELEASE

Approved

Aug 2016

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

3/8 — Basic

DOXYLAMINE SUCCINATE AND PYRIDOXINE HYDROCHLORIDE (doxylamine succinate and pyridoxine hydrochloride) by Teva is delayed-release tablets is unknown. Approved for nausea, vomiting of pregnancy in women. First approved in 2016.

Drug data last refreshed 18h ago

Mechanism of Action

delayed-release tablets is unknown.

Indications (2)

nausea vomiting of pregnancy in women

Company

Worked on DOXYLAMINE SUCCINATE AND PYRIDOXINE HYDROCHLORIDE at Teva? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.